The liver is the central metabolic organ and produces 85–90% of the proteins found in plasma. Accordingly, the plasma proteome is an attractive source of liver disease biomarkers that reflects the different cell types present in this organ, as well as the processes such as responses to acute and chronic injury or the formation of an extracellular matrix. In the first part, we summarize the biomarkers routinely used in clinical evaluations and their biological relevance in the different stages of non-malignant liver disease. Later, we describe the current proteomic approaches, including mass spectrometry and affinity-based techniques, that allow a more comprehensive assessment of the liver function but also require complex data processing. The many approaches of analysis and interpretation and their potential caveats are delineated. While these advances hold the promise to transform our understanding of liver diseases and support the development and validation of new liver-related drugs, an interdisciplinary collaboration is needed.
Colitis-associated colorectal cancer (CAC) develops in the setting of long-standing intestinal inflammation and remains a major complication of inflammatory bowel disease (IBD). Although effective control of inflammation may reduce cancer risk, approaches that specifically prevent the progression from chronic colitis to neoplasia remain limited. Disruption of the gut microbiota–metabolism–immunity axis is increasingly implicated in this process, as microbial dysbiosis and altered metabolite production can compromise epithelial barrier integrity, sustain inflammatory signaling, and disturb mucosal immune homeostasis. This review examines how active components derived from traditional Chinese medicine (TCM), particularly flavonoids, alkaloids, saponins, and polysaccharides, influence this interconnected network in CAC-related models. Rather than treating these constituents as a single group, we compare the mechanistic patterns and evidence base associated with each class. Flavonoids and alkaloids have been studied mainly in relation to inflammatory signaling and epithelial barrier protection, whereas saponins are more often linked to regulation of the immune microenvironment. Polysaccharides have been studied most frequently in relation to microbiota remodeling, short-chain fatty acid production, and mucosal immune balance. These distinctions are not absolute, and substantial overlap exists across component classes. Moreover, most evidence is derived from animal or cell-based studies, with marked variation in experimental models, compound characterizations, dosing, and outcome assessments. The microbiota–metabolism–immunity axis provides a coherent framework for interpreting the multi-level actions of TCM-derived components, but their causal mechanisms and clinical relevance to human CAC require further validation.